Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR0302 for induction and maintenance treatment of moderately to severely active ulcerative colitis
CTR20212938Phase 3Active
- Sponsor
- Reistone Biopharma
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in autoimmune colitis, sponsored by Reistone Biopharma. Started Feb 2022; status: active.
02
Drugs
ivarmacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20212938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212938.